Literature DB >> 26005181

Association of serum leptin with future left ventricular structure and function: The Multi-Ethnic Study of Atherosclerosis (MESA).

Shishir Sharma1, Laura A Colangelo1, Matthew A Allison2, Joao A C Lima3, Bharath Ambale-Venkatesh3, Satoru Kishi3, Kiang Liu1, Philip Greenland4.   

Abstract

BACKGROUND/
OBJECTIVES: Earlier studies differ on whether serum leptin is associated with adverse or beneficial cardiac structure. We determined the association between serum leptin with subsequent cardiac structure and function.
METHODS: MESA is a multicenter longitudinal study of Black, White, Hispanic and Asian-American men and women. Cardiac MRI (CMR) was completed 6 to 8 years after leptin was measured. Left ventricular (LV) mass and volumes were indexed to body surface area. Multivariable linear regression models were constructed to assess the associations between leptin and risk factor adjusted (age, race, gender, systolic blood pressure, anti-hypertensive usage, LDL, HDL, hyperlipidemia medication usage, diabetes, diabetic medication usage, chronic kidney disease, alcohol and tobacco use, adiponectin and BMI) CMR variables.
RESULTS: Relative to participants in the lowest quintile of leptin concentration, participants in the highest quintile had a lower risk factor adjusted LV mass (-14 g), LV mass index (-9 g/m(2)), LV end diastolic volume index (LVEDVi) (-7 ml/m(2)), LV end systolic volume index (LVESVi) (-3 ml/m(2)) and stroke volume (-5 ml) (all p≤0.05). On regression analysis, a doubling of leptin concentration was associated with lower LV mass (-2.5 g ± 0.7 g), LV mass index (-1.7 ± 0.3g/m(2)), LVEDVi (-1.5 ± 0.4 ml/m(2)), LVESVi (-0.7 ± 0.2 ml/m(2)) and stroke volume (-1.0 ± 0.5 ml) (all p ≤ 0.05).
CONCLUSIONS: Higher leptin was associated with more favorable subsequent cardiac structure. Further study is needed to assess the prognostic and therapeutic implications of these observations.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Adipokine; Cardiac structure; Left ventricular mass; Leptin

Mesh:

Substances:

Year:  2015        PMID: 26005181      PMCID: PMC4465987          DOI: 10.1016/j.ijcard.2015.05.068

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  27 in total

Review 1.  Left ventricular remodeling after myocardial infarction: pathophysiology and therapy.

Authors:  M G Sutton; N Sharpe
Journal:  Circulation       Date:  2000-06-27       Impact factor: 29.690

2.  Reduction of obesity, as induced by leptin, reverses endothelial dysfunction in obese (Lep(ob)) mice.

Authors:  B Winters; Z Mo; E Brooks-Asplund; S Kim; A Shoukas; D Li; D Nyhan; D E Berkowitz
Journal:  J Appl Physiol (1985)       Date:  2000-12

3.  Leptin causes nitric-oxide independent coronary artery vasodilation in humans.

Authors:  Keiji Matsuda; Hiroki Teragawa; Yukihiro Fukuda; Keigo Nakagawa; Yukihito Higashi; Kazuaki Chayama
Journal:  Hypertens Res       Date:  2003-02       Impact factor: 3.872

4.  Plasma leptin level is associated with myocardial wall thickness in hypertensive insulin-resistant men.

Authors:  G Paolisso; M R Tagliamonte; M Galderisi; G A Zito; A Petrocelli; C Carella; O de Divitiis; M Varricchio
Journal:  Hypertension       Date:  1999-11       Impact factor: 10.190

5.  Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A.

Authors:  S I Yamagishi ; D Edelstein; X L Du; Y Kaneda; M Guzmán; M Brownlee
Journal:  J Biol Chem       Date:  2001-05-07       Impact factor: 5.157

6.  Leptin attenuates cardiac apoptosis after chronic ischaemic injury.

Authors:  Kenneth R McGaffin; Baobo Zou; Charles F McTiernan; Christopher P O'Donnell
Journal:  Cardiovasc Res       Date:  2009-02-20       Impact factor: 10.787

7.  Interstitial fibrosis, left ventricular remodeling, and myocardial mechanical behavior in a population-based multiethnic cohort: the Multi-Ethnic Study of Atherosclerosis (MESA) study.

Authors:  Sirisha Donekal; Bharath A Venkatesh; Yuan Chang Liu; Chia-Ying Liu; Kihei Yoneyama; Colin O Wu; Marcelo Nacif; Antoinette S Gomes; W Gregory Hundley; David A Bluemke; Joao A C Lima
Journal:  Circ Cardiovasc Imaging       Date:  2014-02-18       Impact factor: 7.792

8.  Relation of leptin to left ventricular hypertrophy (from the Multi-Ethnic Study of Atherosclerosis).

Authors:  Matthew A Allison; David A Bluemke; Robyn McClelland; Mary Cushman; Michael H Criqui; Joseph F Polak; Joao A Lima
Journal:  Am J Cardiol       Date:  2013-05-24       Impact factor: 2.778

9.  Multi-Ethnic Study of Atherosclerosis: objectives and design.

Authors:  Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy
Journal:  Am J Epidemiol       Date:  2002-11-01       Impact factor: 4.897

10.  Association of left ventricular mass with all-cause mortality, myocardial infarction and stroke.

Authors:  Alberto Bouzas-Mosquera; Francisco J Broullón; Nemesio Álvarez-García; Jesús Peteiro; Víctor X Mosquera; Alfonso Castro-Beiras
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

View more
  2 in total

1.  Association of Circulating Adipokines With Echocardiographic Measures of Cardiac Structure and Function in a Community-Based Cohort.

Authors:  Beatrice von Jeinsen; Meghan I Short; Vanessa Xanthakis; Herman Carneiro; Susan Cheng; Gary F Mitchell; Ramachandran S Vasan
Journal:  J Am Heart Assoc       Date:  2018-06-21       Impact factor: 5.501

2.  Association of serum leptin and adiponectin concentrations with echocardiographic parameters and pathophysiological states in patients with cardiovascular disease receiving cardiovascular surgery.

Authors:  Tatsuya Sawaguchi; Toshiaki Nakajima; Akiko Haruyama; Takaaki Hasegawa; Ikuko Shibasaki; Takafumi Nakajima; Hiroyuki Kaneda; Takuo Arikawa; Syotaro Obi; Masashi Sakuma; Hironaga Ogawa; Yuusuke Takei; Shigeru Toyoda; Fumitaka Nakamura; Shichiro Abe; Hirotsugu Fukuda; Teruo Inoue
Journal:  PLoS One       Date:  2019-11-08       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.